logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line

< Back

Infigratinib for unresectable locally advanced or metastatic cholangiocarinoma with FGFR2 rearrangements – second line

Drugs

Cancer and Palliative Care

August 2021


Cholangiocarcinoma (CCA) is a rare type of cancer that affects the bile ducts. Locally advanced CCA is when the cancer spreads from its original site to surround areas, but has not spread to other parts of the body. Metastatic CCA is when the cancer has spread to other areas of the body. Current treatment options for patients with locally advanced and metastatic CCA, who have progressed following chemotherapy are limited.
Infigratinib is an oral capsule that is taken once daily every three out of four weeks. It works by targeting fibroblast growth factor receptor 2 (FGFR2) mutations, which commonly promote cancer growth and spread, by doing so it inhibits this process. Infigratinib is in development for people who have inoperable locally advanced or metastatic CCA with the presence of FGFR2 mutations. If licenced infigratinib would offer a second line or greater treatment option for these patients.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts